SCEMBLIX is the first and only inhibitor that binds to the ABL myristoyl pocket.1 The myristoyl pocket is a distinct site of the kinase domain, normally occupied by the myristoylated N-terminal of ABL1 in people who do not have CML.2
In studies conducted in vitro or in animal models of CML, SCEMBLIX showed activity against wild-type BCR::ABL1 and several mutant forms of the kinase, including the T315I mutation.1
Myelosuppression
Thrombocytopenia, neutropenia, and anemia, including grade 3/4 reactions, have occurred in patients receiving SCEMBLIX
Perform complete blood counts every 2 weeks for the first 3 months of treatment and monthly thereafter or as clinically indicated. Monitor patients for signs and symptoms of myelosuppression...
SCEMBLIX is indicated for the treatment of adult patients with:
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
Ph+ CML in CP with the T315I mutation...